<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00477711</url>
  </required_header>
  <id_info>
    <org_study_id>EMR 62202-769</org_study_id>
    <nct_id>NCT00477711</nct_id>
  </id_info>
  <brief_title>A Study of Cetuximab(Erbitux) With Cisplatin and Capecitabine(Xeloda)as 1st Line Treatment in the Advanced Gastric Cancer</brief_title>
  <acronym>EXTRA</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate whether cetuximab (Erbitux®) with cisplatin and&#xD;
      capecitabine (Xeloda) as 1st line treatment in the advanced gastric cancer is effective.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gastric cancer remains one of the major causes of cancer deaths around the world, especially&#xD;
      in Asia. Previous study of ML17032 has proved that XP(capecitabine plus cisplatin)is&#xD;
      effective in advanced gastric cancer, with the overall response rate of 41%, the median PFS&#xD;
      of 5.6 month. Recently, the EGFR monoclonal antibody of cetuximab has shown to be successful&#xD;
      in treating advanced colorectal cancer with or without chemotherapy. Since EGFR also express&#xD;
      in gastric cancer, A single arm, open, multicenter phase II study of cetuximab in combination&#xD;
      with cisplatin and capecitabine as first line treatment in patient with advanced gastric&#xD;
      cancer.If applicable, the value of mutations in k-ras, b-raf, P53, and EGFR copy number to&#xD;
      predict the clinical response to cetuximab in advanced gastric cancer patients will also be&#xD;
      accessed.Tumor tissue from study patients will be checked for k-ras, b-raf, and P53 mutation&#xD;
      by sequencing and for EGFR copy number by chromogenic in situ hybridization. DNA will be&#xD;
      extracted from paraffin-embedded samples.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor response rate</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression Disease control rate Overall survival K-ras, b-raf, p53 gene mutation and EGFR gene copy number vs. tumor response safety</measure>
    <time_frame>5 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>C225+Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cetuximab, cisplatin, capecitabine</intervention_name>
    <description>Product 1: Cetuximab(Erbitux®) Dosing schedule: 400mg/m2 initial dose and then 250mg/m2 ,weekly dose Mode of administration: intravenously Product 2: capecitabine Dosing schedule: 1000mg/m2 bid, days 1-14, every 3 weeks Mode of administration: orally Product 3: cisplatin Dosing schedule: 80mg/m2, day 1 of every 3 weeks Mode of administration: intravenously</description>
    <arm_group_label>C225+Chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Having signed informed consent&#xD;
&#xD;
          -  Age 18 to 75 years old&#xD;
&#xD;
          -  Histologically confirmed gastric adenocarcinoma&#xD;
&#xD;
          -  Unresectable recurrent or metastatic disease&#xD;
&#xD;
          -  Previous neo-adjuvant or adjuvant treatment for gastric cancer, if applicable, more&#xD;
             than 12 months&#xD;
&#xD;
          -  Measurable disease according to the RECIST criteria&#xD;
&#xD;
          -  Karnofsky performance status ≥60&#xD;
&#xD;
          -  Life expectancy of ≥2 month&#xD;
&#xD;
          -  No prior radiotherapy except radiotherapy at non-target lesion of the study more than&#xD;
             4 weeks&#xD;
&#xD;
          -  ALT and AST&lt;2.5 times ULN (≤5 times ULN in patients with liver metastases)&#xD;
&#xD;
          -  Serum albumin level ≥3.0g/dL&#xD;
&#xD;
          -  Serum AKP &lt; 2.5 times ULN&#xD;
&#xD;
          -  Serum creatinine &lt;1.5mg/dL&#xD;
&#xD;
          -  Bilirubin level &lt; 1.5mg/dL&#xD;
&#xD;
          -  Serum creatinine &lt;1.5 times ULN&#xD;
&#xD;
          -  WBC&gt;3,000/mm3, absolute neutrophil count ≥2000/mm3, platelet&gt;100,000/mm3, Hb&gt;9g/dl&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Brain metastasis (known or suspected)&#xD;
&#xD;
          -  Previous systemic therapy for metastatic gastric cancer&#xD;
&#xD;
          -  Inability to take oral medication&#xD;
&#xD;
          -  Previous EGFR pathway-targeting therapy&#xD;
&#xD;
          -  Surgery (excluding diagnostic biopsy) within 4 weeks prior to study entry&#xD;
&#xD;
          -  Heart failure, coronary artery disease, myocardial infarction within the last 6 months&#xD;
&#xD;
          -  Known allergy to any study treatment&#xD;
&#xD;
          -  Pregnancy or lactation period&#xD;
&#xD;
          -  Any investigational agent within the past 28 days&#xD;
&#xD;
          -  Other previous malignancy within 5 year, except non-melanoma skin cancer&#xD;
&#xD;
          -  Previous adjuvant therapy with capecitabine+platinum&#xD;
&#xD;
          -  Pre-existing neuropathy&gt;grade 1&#xD;
&#xD;
          -  Legal incapacity&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lin Shen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University, School of oncology, Gastrointestinal Department</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peking University,School of Oncology, Gastrointestinal Department</name>
      <address>
        <city>Beijing</city>
        <zip>100036</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <study_first_submitted>May 22, 2007</study_first_submitted>
  <study_first_submitted_qc>May 22, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2007</study_first_posted>
  <last_update_submitted>May 17, 2015</last_update_submitted>
  <last_update_submitted_qc>May 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Shen Lin</investigator_full_name>
    <investigator_title>pro.</investigator_title>
  </responsible_party>
  <keyword>Cetuximab</keyword>
  <keyword>cisplatin</keyword>
  <keyword>capecitabine</keyword>
  <keyword>first line treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

